Cargando…

Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis

Chemokine synergy-inducing molecules are emerging as regulating factors in cell migration. The alarmin HMGB1, in its reduced form, can complex with CXCL12 enhancing its activity on monocytes via the chemokine receptor CXCR4, while the form containing a disulfide bond, by binding to TLR2 or TLR4, ini...

Descripción completa

Detalles Bibliográficos
Autores principales: Cecchinato, Valentina, D'Agostino, Gianluca, Raeli, Lorenzo, Nerviani, Alessandra, Schiraldi, Milena, Danelon, Gabriela, Manzo, Antonio, Thelen, Marcus, Ciurea, Adrian, Bianchi, Marco E., Rubartelli, Anna, Pitzalis, Costantino, Uguccioni, Mariagrazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157448/
https://www.ncbi.nlm.nih.gov/pubmed/30283452
http://dx.doi.org/10.3389/fimmu.2018.02118
_version_ 1783358273645182976
author Cecchinato, Valentina
D'Agostino, Gianluca
Raeli, Lorenzo
Nerviani, Alessandra
Schiraldi, Milena
Danelon, Gabriela
Manzo, Antonio
Thelen, Marcus
Ciurea, Adrian
Bianchi, Marco E.
Rubartelli, Anna
Pitzalis, Costantino
Uguccioni, Mariagrazia
author_facet Cecchinato, Valentina
D'Agostino, Gianluca
Raeli, Lorenzo
Nerviani, Alessandra
Schiraldi, Milena
Danelon, Gabriela
Manzo, Antonio
Thelen, Marcus
Ciurea, Adrian
Bianchi, Marco E.
Rubartelli, Anna
Pitzalis, Costantino
Uguccioni, Mariagrazia
author_sort Cecchinato, Valentina
collection PubMed
description Chemokine synergy-inducing molecules are emerging as regulating factors in cell migration. The alarmin HMGB1, in its reduced form, can complex with CXCL12 enhancing its activity on monocytes via the chemokine receptor CXCR4, while the form containing a disulfide bond, by binding to TLR2 or TLR4, initiates a cascade of events leading to production of cytokines and chemokines. So far, the possibility that the CXCL12/HMGB1 heterocomplex could be maintained in chronic inflammation was debated, due to the release of reactive oxygen species. Therefore, we have assessed if the heterocomplex could remain active in Rheumatoid Arthritis (RA) and its relevance in the disease assessment. Monocytes from RA patients with active disease require a low concentration of HMGB1 to enhance CXCL12-induced migration, in comparison to monocytes from patients in clinical remission or healthy donors. The activity of the heterocomplex depends on disease activity, on the COX2 and JAK/STAT pathways, and is determined by the redox potential of the microenvironment. In RA, the presence of an active thioredoxin system correlates with the enhanced cell migration, and with the presence of the heterocomplex in the synovial fluid. The present study highlights how, in an unbalanced microenvironment, the activity of the thioredoxin system plays a crucial role in sustaining inflammation. Prostaglandin E2 stimulation of monocytes from healthy donors is sufficient to recapitulate the response observed in patients with active RA. The activation of mechanisms counteracting the oxidative stress in the extracellular compartment preserves HMGB1 in its reduced form, and contributes to fuel the influx of inflammatory cells. Targeting the heterocomplex formation and its activity could thus be an additional tool for dampening the inflammation sustained by cell recruitment, for those patients with chronic inflammatory conditions who poorly respond to current therapies.
format Online
Article
Text
id pubmed-6157448
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61574482018-10-03 Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis Cecchinato, Valentina D'Agostino, Gianluca Raeli, Lorenzo Nerviani, Alessandra Schiraldi, Milena Danelon, Gabriela Manzo, Antonio Thelen, Marcus Ciurea, Adrian Bianchi, Marco E. Rubartelli, Anna Pitzalis, Costantino Uguccioni, Mariagrazia Front Immunol Immunology Chemokine synergy-inducing molecules are emerging as regulating factors in cell migration. The alarmin HMGB1, in its reduced form, can complex with CXCL12 enhancing its activity on monocytes via the chemokine receptor CXCR4, while the form containing a disulfide bond, by binding to TLR2 or TLR4, initiates a cascade of events leading to production of cytokines and chemokines. So far, the possibility that the CXCL12/HMGB1 heterocomplex could be maintained in chronic inflammation was debated, due to the release of reactive oxygen species. Therefore, we have assessed if the heterocomplex could remain active in Rheumatoid Arthritis (RA) and its relevance in the disease assessment. Monocytes from RA patients with active disease require a low concentration of HMGB1 to enhance CXCL12-induced migration, in comparison to monocytes from patients in clinical remission or healthy donors. The activity of the heterocomplex depends on disease activity, on the COX2 and JAK/STAT pathways, and is determined by the redox potential of the microenvironment. In RA, the presence of an active thioredoxin system correlates with the enhanced cell migration, and with the presence of the heterocomplex in the synovial fluid. The present study highlights how, in an unbalanced microenvironment, the activity of the thioredoxin system plays a crucial role in sustaining inflammation. Prostaglandin E2 stimulation of monocytes from healthy donors is sufficient to recapitulate the response observed in patients with active RA. The activation of mechanisms counteracting the oxidative stress in the extracellular compartment preserves HMGB1 in its reduced form, and contributes to fuel the influx of inflammatory cells. Targeting the heterocomplex formation and its activity could thus be an additional tool for dampening the inflammation sustained by cell recruitment, for those patients with chronic inflammatory conditions who poorly respond to current therapies. Frontiers Media S.A. 2018-09-19 /pmc/articles/PMC6157448/ /pubmed/30283452 http://dx.doi.org/10.3389/fimmu.2018.02118 Text en Copyright © 2018 Cecchinato, D'Agostino, Raeli, Nerviani, Schiraldi, Danelon, Manzo, Thelen, Ciurea, Bianchi, Rubartelli, Pitzalis and Uguccioni. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Cecchinato, Valentina
D'Agostino, Gianluca
Raeli, Lorenzo
Nerviani, Alessandra
Schiraldi, Milena
Danelon, Gabriela
Manzo, Antonio
Thelen, Marcus
Ciurea, Adrian
Bianchi, Marco E.
Rubartelli, Anna
Pitzalis, Costantino
Uguccioni, Mariagrazia
Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis
title Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis
title_full Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis
title_fullStr Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis
title_full_unstemmed Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis
title_short Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis
title_sort redox-mediated mechanisms fuel monocyte responses to cxcl12/hmgb1 in active rheumatoid arthritis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157448/
https://www.ncbi.nlm.nih.gov/pubmed/30283452
http://dx.doi.org/10.3389/fimmu.2018.02118
work_keys_str_mv AT cecchinatovalentina redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT dagostinogianluca redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT raelilorenzo redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT nervianialessandra redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT schiraldimilena redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT danelongabriela redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT manzoantonio redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT thelenmarcus redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT ciureaadrian redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT bianchimarcoe redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT rubartellianna redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT pitzaliscostantino redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis
AT uguccionimariagrazia redoxmediatedmechanismsfuelmonocyteresponsestocxcl12hmgb1inactiverheumatoidarthritis